Pre-Made Abatacept Biosimilar, Fusion Protein targeting CTLA4/CTLA-4 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-712

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-712 Category Tag

Product Details

Pre-Made Abatacept Biosimilar, Fusion Protein targeting CTLA4/CTLA-4 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Abatacept, sold under the brand name Orencia, is a medication used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. It is a modified antibody.

Abatacept is used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. In order for a T cell to be activated and produce an immune response, an antigen-presenting cell must present two signals to the T cell. One of those signals is the major histocompatibility complex (MHC), combined with the antigen, and the other signal is the CD80 or CD86 molecule. Abatacept binds to the CD80 and CD86 molecule, and prevents the second signal. Without the second signal, the T cell can’t be activated. It also used to treat psoriatic arthritis and juvenile idiopathic arthritis.

Products Name (INN Index)

Pre-Made Abatacept Biosimilar, Fusion Protein targeting CTLA4/CTLA-4 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3

INN Name

abatacept

Target

CTLA4

Format

Fusion Protein

Derivation

Human

Species Reactivity

Human

CH1 Isotype

Fusion – [CTLA4 (cytotoxic T- lymphocyte- associated protein 4, CD152)]2 – IGHG1 Fc (Fragment constant)

VD LC

Fusion – [CTLA4 (cytotoxic T- lymphocyte- associated protein 4, CD152)]2 – IGHG1 Fc (Fragment constant)

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Bristol-Myers Squibb (Princeton NJ USA)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

ctla-4

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide